Roche’s Tecentriq is showing new promise as an early treatment for bladder cancer.
The immunotherapy has already been approved to treat the disease, but Roche has been evaluating in combination with chemo for early or advanced forms of bladder cancer.
According to the company, results from a phase 3 trial showed that when combined with chemo, Tecentriq reduced the risk of death and delayed worsening of the disease, when compared to chemo alone. The results mean that the study met its targets.
Roche plans to share the trial outcome with regulatory bodies in the U.S. and EU.
Read the Reuters report.
